UniProt ID | RS13_HUMAN | |
---|---|---|
UniProt AC | P62277 | |
Protein Name | 40S ribosomal protein S13 | |
Gene Name | RPS13 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 151 | |
Subcellular Localization | ||
Protein Description | ||
Protein Sequence | MGRMHAPGKGLSQSALPYRRSVPTWLKLTSDDVKEQIYKLAKKGLTPSQIGVILRDSHGVAQVRFVTGNKILRILKSKGLAPDLPEDLYHLIKKAVAVRKHLERNRKDKDAKFRLILIESRIHRLARYYKTKRVLPPNWKYESSTASALVA | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
9 | 2-Hydroxyisobutyrylation | GRMHAPGKGLSQSAL CCCCCCCCCCCCCCC | 56.47 | - | |
9 | Ubiquitination | GRMHAPGKGLSQSAL CCCCCCCCCCCCCCC | 56.47 | 23000965 | |
9 | Acetylation | GRMHAPGKGLSQSAL CCCCCCCCCCCCCCC | 56.47 | 26051181 | |
12 | Phosphorylation | HAPGKGLSQSALPYR CCCCCCCCCCCCCCC | 30.66 | 21712546 | |
14 | Phosphorylation | PGKGLSQSALPYRRS CCCCCCCCCCCCCCC | 28.53 | 30108239 | |
18 | Phosphorylation | LSQSALPYRRSVPTW CCCCCCCCCCCCCCE | 21.36 | 28152594 | |
21 | Phosphorylation | SALPYRRSVPTWLKL CCCCCCCCCCCEEEC | 24.37 | 20068231 | |
24 | Phosphorylation | PYRRSVPTWLKLTSD CCCCCCCCEEECCCH | 41.07 | 20068231 | |
27 | Succinylation | RSVPTWLKLTSDDVK CCCCCEEECCCHHHH | 41.08 | - | |
27 | Succinylation | RSVPTWLKLTSDDVK CCCCCEEECCCHHHH | 41.08 | 21890473 | |
27 | Ubiquitination | RSVPTWLKLTSDDVK CCCCCEEECCCHHHH | 41.08 | 27667366 | |
27 | 2-Hydroxyisobutyrylation | RSVPTWLKLTSDDVK CCCCCEEECCCHHHH | 41.08 | - | |
27 | Acetylation | RSVPTWLKLTSDDVK CCCCCEEECCCHHHH | 41.08 | 19608861 | |
29 | Phosphorylation | VPTWLKLTSDDVKEQ CCCEEECCCHHHHHH | 28.64 | 19691289 | |
30 | Phosphorylation | PTWLKLTSDDVKEQI CCEEECCCHHHHHHH | 42.10 | 19691289 | |
34 | Ubiquitination | KLTSDDVKEQIYKLA ECCCHHHHHHHHHHH | 51.39 | 23000965 | |
34 | Succinylation | KLTSDDVKEQIYKLA ECCCHHHHHHHHHHH | 51.39 | - | |
34 | Succinylation | KLTSDDVKEQIYKLA ECCCHHHHHHHHHHH | 51.39 | 23954790 | |
34 | Acetylation | KLTSDDVKEQIYKLA ECCCHHHHHHHHHHH | 51.39 | 25825284 | |
38 | Phosphorylation | DDVKEQIYKLAKKGL HHHHHHHHHHHHCCC | 10.31 | 27155012 | |
39 | Acetylation | DVKEQIYKLAKKGLT HHHHHHHHHHHCCCC | 43.53 | 23749302 | |
39 | Ubiquitination | DVKEQIYKLAKKGLT HHHHHHHHHHHCCCC | 43.53 | 23000965 | |
39 | Malonylation | DVKEQIYKLAKKGLT HHHHHHHHHHHCCCC | 43.53 | 26320211 | |
42 | Ubiquitination | EQIYKLAKKGLTPSQ HHHHHHHHCCCCHHH | 58.78 | 23000965 | |
43 | Sumoylation | QIYKLAKKGLTPSQI HHHHHHHCCCCHHHH | 54.25 | 28112733 | |
43 | Malonylation | QIYKLAKKGLTPSQI HHHHHHHCCCCHHHH | 54.25 | 26320211 | |
43 | Ubiquitination | QIYKLAKKGLTPSQI HHHHHHHCCCCHHHH | 54.25 | 23000965 | |
43 | Acetylation | QIYKLAKKGLTPSQI HHHHHHHCCCCHHHH | 54.25 | 26051181 | |
46 | Phosphorylation | KLAKKGLTPSQIGVI HHHHCCCCHHHHEEE | 29.57 | - | |
48 | Phosphorylation | AKKGLTPSQIGVILR HHCCCCHHHHEEEEE | 29.24 | 28450419 | |
57 | Phosphorylation | IGVILRDSHGVAQVR HEEEEECCCCEEEEE | 18.73 | 20860994 | |
70 | Ubiquitination | VRFVTGNKILRILKS EEEEEHHHHHHHHHH | 44.45 | 23000965 | |
70 | 2-Hydroxyisobutyrylation | VRFVTGNKILRILKS EEEEEHHHHHHHHHH | 44.45 | - | |
76 | Ubiquitination | NKILRILKSKGLAPD HHHHHHHHHCCCCCC | 47.99 | 23000965 | |
78 | Ubiquitination | ILRILKSKGLAPDLP HHHHHHHCCCCCCCC | 57.25 | 23000965 | |
78 | 2-Hydroxyisobutyrylation | ILRILKSKGLAPDLP HHHHHHHCCCCCCCC | 57.25 | - | |
78 | Acetylation | ILRILKSKGLAPDLP HHHHHHHCCCCCCCC | 57.25 | 26051181 | |
89 | Phosphorylation | PDLPEDLYHLIKKAV CCCCHHHHHHHHHHH | 13.60 | - | |
93 | 2-Hydroxyisobutyrylation | EDLYHLIKKAVAVRK HHHHHHHHHHHHHHH | 40.83 | - | |
93 | Ubiquitination | EDLYHLIKKAVAVRK HHHHHHHHHHHHHHH | 40.83 | 21906983 | |
93 | Acetylation | EDLYHLIKKAVAVRK HHHHHHHHHHHHHHH | 40.83 | 26051181 | |
94 | Ubiquitination | DLYHLIKKAVAVRKH HHHHHHHHHHHHHHH | 40.89 | 22817900 | |
107 | Ubiquitination | KHLERNRKDKDAKFR HHHHHCCCCCCCCHH | 73.08 | 24816145 | |
109 | Ubiquitination | LERNRKDKDAKFRLI HHHCCCCCCCCHHHH | 63.72 | 24816145 | |
112 | 2-Hydroxyisobutyrylation | NRKDKDAKFRLILIE CCCCCCCCHHHHHHH | 40.94 | - | |
120 | Phosphorylation | FRLILIESRIHRLAR HHHHHHHHHHHHHHH | 29.55 | 21712546 | |
128 | Phosphorylation | RIHRLARYYKTKRVL HHHHHHHHHCCCCCC | 12.05 | 22817900 | |
129 | Phosphorylation | IHRLARYYKTKRVLP HHHHHHHHCCCCCCC | 13.46 | 17081983 | |
141 | Phosphorylation | VLPPNWKYESSTASA CCCCCCCCCCCCCHH | 16.80 | 28152594 | |
143 | Phosphorylation | PPNWKYESSTASALV CCCCCCCCCCCHHHC | 29.87 | 28152594 | |
144 | Phosphorylation | PNWKYESSTASALVA CCCCCCCCCCHHHCC | 18.95 | 28152594 | |
145 | Phosphorylation | NWKYESSTASALVA- CCCCCCCCCHHHCC- | 33.63 | 28152594 | |
147 | Phosphorylation | KYESSTASALVA--- CCCCCCCHHHCC--- | 23.40 | 28152594 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of RS13_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of RS13_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RS13_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-27 AND LYS-39, AND MASSSPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12, AND MASSSPECTROMETRY. | |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-128 AND TYR-129, ANDMASS SPECTROMETRY. | |
"Immunoaffinity profiling of tyrosine phosphorylation in cancercells."; Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,Zha X.-M., Polakiewicz R.D., Comb M.J.; Nat. Biotechnol. 23:94-101(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-38, AND MASSSPECTROMETRY. |